Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s ...
Almost two years after finally pulling the plug on a big non-opioid painkiller programme, Eli Lilly has ... royalty rate. Lilly’s last attempt to develop a non-opioid pain drug was with Pfizer ...
One of the highlights of Eli Lilly's third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro, which added more than $97 million in US sales alone in what has been ...
China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option after Eisai and Biogen's Leqembi received approval in January ...
Some experts even expect Eli Lilly to be the world’s first healthcare company to hit $1.00 trillion valuation on the back of its weight-loss initiative. What the licensing deal means for Merck ...